Palliative Radiotherapy in Metastatic Breast Cancer Patients on CDK4/6 Inhibitors: Safety Analysis
The concurrent use of CDK4/6 inhibitors and palliative radiotherapy does not increase the incidence of hematological adverse events in patients with metastatic breast cancer.
Authors
- Furkan Ceylan (ORCID: https://orcid.org/0000-0002-1944-0861)
- Burak Bi̇lgi̇n (ORCID: https://orcid.org/0000-0003-1717-8246)
- Didem Şener Dede (ORCID: https://orcid.org/0000-0002-9756-5942)
- Mehmet Alı Nahıt Şendur (ORCID: https://orcid.org/0000-0001-7021-6139)
- Efnan Algın (ORCID: https://orcid.org/0000-0002-8917-9267)
- Şebnem Çınar Yücel (ORCID: https://orcid.org/0000-0002-8904-7395)
- Muhammed Bülent Akıncı (ORCID: https://orcid.org/0000-0001-7575-9925)
- Ateş Kutay Tenekeci (ORCID: https://orcid.org/0009-0007-6224-945X)
- Bülent Yalçın (ORCID: https://orcid.org/0000-0002-4431-8948)
- Mirmehdi Mehdiyev
Institutions
- Memorial Ankara Hospital (TR)
- Ankara Yıldırım Beyazıt University (TR)
- Ankara Bilkent City Hospital (TR)
- Hacettepe University (TR)
Publication Details
- Journal
- Cancers
- Published
- 2025-01-27
- DOI
- https://doi.org/10.3390/cancers17030424
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52